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Abstract 
To understand why vaccine-activated tumor-specific T cells often fail to generate antitumor effects, 
we studied two-fetoprotein–specific CD8+ T cells (Tet499 and Tet212) that had different antitumor effects. 
We found that Tet499 required high antigen doses for re-activation, but could survive persistent antigen 
stimulation and maintain their effector functions. In contrast, Tet212 had a low threshold of re-activation, 
but underwent exhaustion and apoptosis in the presence of persistent antigen. In vivo, Tet499 cells 
expanded more than Tet212 upon re-encountering antigen and generated stronger antitumor effects. The 
different antigen responsiveness and antitumor effects of Tet212 and Tet499 cells correlated with their 
activation and differentiation states. Compared to Tet212, the population of Tet499 cells was less activated 
and contained more stem-like memory T cells (Tscm) that could undergo expansion in vivo. The TCR 
signaling strength on Tet499 was weaker than Tet212, correlating with more severe Tet499 TCR 
downregulation. Weak TCR signaling may halt T-cell differentiation at the Tscm stage during immune 
priming and also explains why Tet499 re-activation requires a high antigen dose. Weak TCR signaling of 
Tet499 cells in the effector stage will also protect them from exhaustion and apoptosis when they re-
encounter persistent antigen in tumor lesion, which generates antitumor effects. Further investigation of 
TCR downregulation and manipulation of TCR signaling strength may help design cancer vaccines to 
elicit a mix of tumor-specific CD8+ T cells, including Tscm, capable of surviving antigen re-stimulation 
to generate antitumor effects. 
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Introduction 
The success of using checkpoint blockade to unleash antitumor immunity (1) confirms that activation 
of the immune system can control cancer growth. Intensive efforts by vaccine researchers have yielded a 
variety of immunization approaches that can elicit tumor-specific immunity (2). Despite induction of 
tumor-specific T cells, however, the antitumor effect of cancer vaccines remains disappointing (3). 
Evidence from both animal models (4,5) and human trials (6) suggests that the presence of tumor 
antigen–specific T cells does not necessarily translate into antitumor effects. The limited antitumor effect 
of tumor-specific T cells has been attributed to immune suppression (7) as well as to T-effector cell (Teff) 
exhaustion (8,9). However, the lack of correlation between the frequency of antigen-specific T cells and 
antitumor effects (10-12) also suggests that intrinsic cell attributes may play a role in determining their 
antitumor outcome (13). Although high “functional avidity” of antigen-specific T cells might be a 
measure of antitumor efficacy (14-16), contrasting evidence shows that high avidity T cells are associated 
with weaker antitumor effects (17,18). Indeed, in chronic infections (19,20), the competitiveness of high-
avidity T cells comes at a cost, i.e., over-activation, exhaustion, and apoptosis of Teff cells in the presence 
of persistent antigen stimulation, a scenario that also exists in tumor lesions. Thus, the attributes of CD8+ 
T cells and mechanisms underpinning the antitumor efficacy of tumor-specific immunity remain unclear 
and require in-depth investigation in order to improve the efficacy of current immunotherapies.  
Lentivector (lv) activates CD8+ T-cell responses (21,22) because of its transduction of dendritic cells 
(23). We found that immunization with lv-expressing epitope-optimized -fetoprotein (opt-AFP) 
activated CD8+ cells to prevent carcinogen-induced autochthonous hepatocellular carcinoma (HCC) in 
mice (24). But it is not clear whether different epitope-specific CD8+ cells all have antitumor effect. In the 
current study, we investigated the antitumor effects of two AFP epitope-specific CD8+ cells that could be 
reproducibly induced by lv immunization. We found that epitope AFP212- and AFP499- specific CD8
+ cells 
(hereafter as Tet212 and Tet499) generated different antitumor effects. We thus studied the molecular and 
cellular attributes of vaccine-activated T cells that are associated with their antitumor effects. We found 
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that Tet499 were insensitive to antigen stimulation and survived persistent in vitro antigen re-stimulation 
and maintained their effector functions. In contrast, Tet212 were sensitive to antigen re-stimulation, 
resulting in more expansion at low doses of antigen, but became exhausted and apoptotic in the presence 
of high and persistent antigen. In vivo, Tet499 generated more expansion than Tet212 upon re-encountering 
antigen. The different antigen responsiveness of Tet212 and Tet499 cells correlated to their different TCR 
signaling strength and the presence of stem-like memory T cells (Tscm), which had robust in vivo 
expansion. The TCR signaling on Tet499 was weaker, associated with severe TCR downregulation. Thus, 
TCR downregulation and weakened TCR signaling likely prevent Tet499 from over-activation and 
enhances Tscm responses in the priming phase, but also protect Teff from exhaustion and apoptosis at 
effector phase. Our data suggest that further investigation into the molecular mechanisms of how to 
control TCR downregulation and TCR signaling strength may help design cancer vaccines to elicit a 
diverse and healthy mix of tumor-specific CD8+ T cells, especially Tscm, to generate antitumor effects.   
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Materials and Methods  
 
Mice 
C57BL/6 (CD45.2 and CD45.1) and C3H mice were from Charles River. Nur77GFP mice (25) 
were from Jackson Laboratory. Mice were bred and maintained in specific pathogen-free facility at 
Augusta University. Animal protocols were approved by the Institutional Animal Care and Use 
Committee. 
Tetramers  
The PE-labeled H-2Db/AFP212 and PE- or APC- labeled H-2K
b-Db/AFP499 tetramers were 
prepared by NIH Tetramer Core Facility. In the H-2Kb-Db/AFP499 Tetramer, the α3 domain of H-2Kb is 
replaced with α3 domain of H-2Db to reduce non-specific binding. The AFP212 and AFP499 peptides bind 
to H-2Db and H-2Kb, respectively. Wild-type AFP peptides were used to prepare tetramers.  
Cell lines, tumor challenge and tumor induction 
EL4 and 293T cells were purchased from ATCC (Manassas, VA) in 2010. Cells received from 
ATCC were immediately expanded and stored in liquid nitrogen. Each time, one vial of cells were thawed 
and used for less than 6 passages to maintain their authenticity. EL4-AFP tumor cells were established 
previously (24) by transducing parental EL4 cells with lv expressing mouse AFP. Cell lines were checked 
for mycoplasma by PCR test (Fisher Scientific). For tumor challenge, 1X105 EL4-AFP cells were injected 
subcutaneously into the flank of C57BL/6 mice. The induction of autochthonous HCC with 
diethylnitrosamine (DEN) (Sigma) was conducted as described (24). Briefly, 2wks old of the F1 mice of 
B6XC3H cross-bred was intraperitoneally injected with 50µg of DEN per gram of mouse weight. 
Recombinant viral vectors and immunization 
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The plasmid expressing epitope-optimized mouse AFP (opt-AFP) was described (24). The shorter 
AFP fragments of AFP142 and AFP164 were cloned into pLenti6 (Invitrogen) by PCR cloning. The lvs 
were prepared by transient co-transfection of 293T cells and the vectors were concentrated and titered by 
measuring the p24 level as described (21).  
To construct recombinant vv expressing the opt-AFP, a shuttle plasmid vector pG10 was used (26). 
The opt-AFP gene was cloned into the vector behind the p7.5 early gene promoter to create pG10-opt-
AFP. CV-1 cells in 6-well plates were infected with a wild-type vaccinia virus of WR strain at 
multiplicity of infection of 0.1, and then transfected with pG10-opt-AFP by SuperFect reagent (Qiagen). 
The recombinant vv was selected in human TK-143 cells with addition of BrdU in the medium. After 
three rounds of plaque purification, the purity of the virus was verified by PCR assays for presence of the 
transgene and deletion of the viral thymidine kinase gene, and by fluorescence of DsRED in the infected 
cells. The virus, designated as opt-AFP-vv, was amplified in HeLa cells and purified by a standard 
procedure (26).  
For immunization, 2X107 transduction units of opt-AFP-lv were injected via footpad. To boost 
immune responses, 1.5 X107 infectious units of recombinant opt-AFP-vv were injected intraperitoneally. 
For immunization in the autochthonous HCC model, 2 months old F1 mice of B6XC3H that had been 
induced by carcinogen DEN were immunized with opt-AFP-lv and then boosted with opt-AFP-vv at 3 
months old.  
 
In vitro re-stimulation 
The splenocytes (6 millions) were re-stimulated for the indicated time with various concentration 
of wild type AFP212 (GSMLNEHVC) or AFP499 (SSYSNRRL) peptide in the presence of 20IU/ml IL-2 
(ProSpec-Tany Technogene). The wild type AFP peptides were used to make sure that the re-stimulated T 
cells would recognize and kill tumor cells expressing wild type AFP. In some experiments, 10ng/ml of 
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IL-7 and IL-15 were also added. To maintain peptide level, half of the RPMI medium containing the 
indicated concentrations of peptides was changed every other day.  
In the second setting, the splenic CD8 T cells were purified by magnetic beads from immunized 
CD45.2 mice. The splenocytes of naïve CD45.1 congenic mice were pulsed with indicated concentrations 
of AFP212 or AFP499 peotides for 2hrs. Free peptides were washed away. Two millions of the purified 
CD8 T cells were then re-stimulated with four millions of peptide-loaded CD45.1 splenocytes in a 24 well 
plate in RPMI media containing 20IU/ml IL-2. After forty-eight hours, four millions of peptide-loaded 
CD45.1 fresh splenocytes were added to continue stimulation for another 2 days before analysis.     
Immunological staining and flow cytometry analysis 
Peripheral mouse blood cells and the splenocytes (fresh or stimulated) were stained with 
indicated combinations of antibodies plus H-2Db/AFP212 or H-2K
b-Db/AFP499 tetramers. For tetramer 
staining after re-stimulation with peptide in the media, the stimulated cells need 12 hours rest to recover 
the TCR. DAPI was added to exclude dead cells. Intracellular staining of IFN was conducted as 
described (24) after the cells were re-stimulated with peptides in the presence of GolgiStop for 3.5 hours. 
Events were collected on the LSR II and the data was analyzed using FCS Express III software. The 
antibodies used in this study include antibodies to mouse CD8 (Clone: 53-6.7, Biolegend), CD45.1 
(Clone: A20, Biolegend), CD45.2 (Clone: 104, BD Bioscience), CD44 (Clone: 1M7, Biolegend), CD62L 
(Clone: MEL-14, Biolegend), CD127 (IL-7Ra) (Clone: A7R34, Biolegend), PD-1 (Clone: 29F.1A12, 
Biolegend), CCR7 (Clone: 4B12, Biolegend), CD122 (IL-2Rβ) (Clone: TM-β1, Biolegend), Sca-1 (Clone: 
D7, Biolegend,), CD95 (Clone: SA367H8, Biolegend), IFN-γ (Clone: XMG1.2, Biolegend), Bcl-2 (Clone: 
BCL/10C4, Biolegend), H-2K b/H-2Db (Clone: 28-8-6, Biolegend), TCRβ (Clone: H57-597, BD 
Bioscience). The Annexin-V and DAPI (4,6-diamidino-2 phenylinole dilactate) were from Biolegend.   
CTL assay  
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The in vitro CTL assay was performed as previous described (21,24). The splenocytes from 
immunized mice were re-stimulated with 2µg/ml of AFP212 or AFP499 peptide for indicated times in the 
RPMI media containing 20 units/ml of IL-2. The EL4 and EL4-AFP tumor cells were labeled with 1µM 
and 0.03µM of 5-(and 6)-Carboxyfluorescein diacetate succinimidyl ester (CFSE) (Invitrogen), 
respectively, for 10min at 37°C. After washing, equal numbers (5X104) of CFSElo-labeled target EL4-
AFP cells and CFSEhi-labeled EL4 control cells were co-cultured in triplicate with the in vitro peptide-
stimulated splenocytes at the indicated E/T ratios for 6 hours. The killing of target EL4-AFP cells was 
analyzed by flow cytometry. The specific killing activity was calculated using the formula [1-(ratio of 
CFSEhi/CFSElo in the absence of CTL) / (ratio of CFSEhi/CFSElo in the presence of CTL)] X100 as 
previously described (21).  
Cell Sorting and Adaptive cell transfer  
The splenic CD8 T cells were enriched by magnetic beads (Stemcell Technologies) then stained 
with anti-CD8, CD44, CD62L antibodies plus H-2Db/mAFP212 or H-2K
b-Db/mAFP499 tetramer. The 
tetramer+ cells and their subsets were sorted on FACSAria (BD Biosciences). The sorted cells of 
indicated number were injected into CD45.1 congenic mice, which were then immunized with opt-AFP-lv. 
The CD45.2+CD8+Tet+ cells in the peripheral blood of CD45.1 mice were monitored once a week by 
tetramer staining. 
 
Tetramer binding and dissociation assay 
The tetramer binding and dissociation assays were conducted as described (27).  For tetramer 
binding assay, one million splenocytes of the immunized mice were stained with anti-CD8 antibody and 
the indicated concentrations of H-2Db/AFP212 or H-2K
b-Db/AFP499 tetramer. Between the tetramer 
concentrations of 6.5µg/ml to 13µg/ml, the percent of Tet212 and Tet499 cells did not increase further, 
suggesting that all the tetramer+ cells were stained. The Tet212 and Tet499 cells detected at lower tetramer 
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concentration were compared to those detected at the concentration of 13µg/ml, which was considered as 
100%.  
For tetramer dissociation assay, the cells were stained with 6.5µg/ml of tetramer. After washing 
away the free tetramers, the cells were left at room temperature for the indicated times in the presence of 
anti-H-2Kb/H-2Db antibody before they were analyzed for the percent and MFI of the Tet+ cells.  
Statistical analysis 
Statistical analyses were performed using T-test or ANOVA (GraphPad Inc). 
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Results 
Tet212 and Tet499 have different CTL activity and in vivo antitumor effects  
To study whether different AFP epitope-specific CD8+ T cells could kill AFP+ tumor cells, we re-
stimulated the splenocytes with AFP212 and AFP499 peptide in media and used them as effectors for in 
vitro CTL assays (Fig. 1A). After 6-day re-stimulation, splenocytes of naïve and wild-type-AFP-lv 
immunized mice showed no CTL activity (Fig.1B), consistent with our recent report (24).  On the other 
hand, splenocytes from the opt-AFP-lv immunized mice had CTL activity after AFP499 peptide re-
stimulation (Fig. 1B and Supplementary Fig. S1A-B). However, after AFP212 peptide re-stimulation, 
splenocytes of the opt-AFP-lv immunized mice generated no CTL activity. Kinetic study demonstrated 
that the CTL activity of opt-AFP-lv immunized splenocytes was diminished with AFP212 peptide, but was 
enhanced with AFP499 peptide, re-stimulation (Supplementary Fig. S1C).  
To study whether Tet212 and Tet499 generated different antitumor effects in vivo, we constructed 
two lvs, AFP142-lv and AFP164-lv, to activate Tet212 and Tet499 separately (Fig. 1C). We found that, like 
opt-AFP-lv, AFP164-lv immunization protected mice from AFP+ tumor challenge. In contrast, all mice 
immunized with AFP142-lv developed tumors (Fig. 1D). The lack of antitumor effect by Tet212 was not 
due to its incapability of recognizing AFP+ tumor cells since both Tet212 and Tet499 cells produced IFN 
after co-culture with EL4-AFP cells (Supplementary Fig. S1D). Together, these data suggest that Tet212 
and Tet499 cells have different responses to tumor antigen in vitro and in vivo, resulting in different 
antitumor effects.  
 
Tet212 cells differ from Tet499  in re-activation threshold, exhaustion and apoptosis  
To investigate why Tet212 and Tet499 generate such different CTL activities and antitumor effects, 
we studied their antigen responsiveness in vitro. To generate more Tet212 and Tet499 cells, we boosted the 
lv-immunized mice with vv. The purified CD8
+
 cells from immunized CD45.2 mice were re-stimulated 
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with naive CD45.1 splenocytes pulsed with different peptides. After 4-days, we observed a dose-
dependent increase of Tet212 cells between the pulsed peptide ranges of 0.1-2µg/ml (Fig. 2A). However, at 
10µg/ml of AFP212 peptide, the percent of Tet212 among total CD45.2 CD8
+ cells began to decline. 
Furthermore, re-stimulation with 2µg/ml of AFP212 peptide in media reduced Tet212 to ~1% (Fig. 2A). In 
contrast, the percent of Tet499 increased only slightly between the pulsed AFP499 peptide ranges of 0.1-
10µg/ml, and increased more so after re-stimulation with AFP499 peptide in media (Fig. 2A). In addition, 
we analyzed the PD1 and Annexin-V level on Tet212 and Tet499 after stimulation. We found that, 
compared to Tet499, the percent of PD1
+ Tet212 and the MFI of PD1 on Tet212 was higher at every dose 
point (Fig. 2B). Similarly, the percent and MFI of Annexin-V were also higher on Tet212 (Fig. 2C). The 
production of cytokine IFN by Tet212 cells was inversely related to AFP212 peptide dose (Fig. 2D-E). In 
contrast, the percent and MFI of IFN+ Tet499 cells were directly related to the dose of AFP499 peptide. 
The exhaustion and apoptosis of Tet212 and Tet499 cells were also studied when peptides were 
added directly to the re-stimulation media (Supplementary Fig. S2A). The data showed ~10% of Tet212 
and Tet499 cells being apoptotic prior to re-stimulation. AFP212 peptide re-stimulation caused Tet212 
undergo dose-dependent apoptosis, ~70% of Tet212 cell being apoptotic with 2µg/ml of peptide 
stimulation (Supplementary Fig. S2B-C). In contrast, only ~17% of Tet499 cells were apoptotic after 
AFP499 peptide re-stimulation. Consistent with the data, only 5% of Tet212 cells, but 80% of Tet499 cells, 
survived 4 day peptide re-stimulation (Supplementary Fig. S2D). Again, more Tet212 expressed higher 
level of PD1 in a dose-dependent manner (Supplementary Fig. S2E). Furthermore, Tet212 lost their 
cytokine production and CTL activity after re-stimulation (Supplementary Fig. S2F). In contrast, the 
majority of Tet499 was not exhausted and maintained their effector function. The exhaustion and apoptosis 
were different from activation-induced anergy (28) as it could not be rescued by the addition of IL2 or 
even IL7 and IL15. 
In summary, Tet212 have a low threshold of re-activation and can be expanded by low dose antigen. 
But its high sensitivity to antigen re-stimulation leads to progressive upregulation of PD1 and reciprocal 
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decrease of IFN and apoptosis with increasing dose of antigen. In contrast, Tet499 have a high re-
activation threshold and thus is difficult to activate and expand. But the Tet499’s insensitivity to antigen 
also protects them from exhaustion and activation-induced apoptosis. As a result, persistent antigen re-
stimulation (such as peptide in media) decreased Tet212 but increased Tet499 cells.  
 
Tet499 proliferate better in vivo than Tet212 in response to emerging tumor antigen.  
We then studied in vivo re-expansion of Tet212 and Tet499 upon re-encountering antigen. Tet212 and 
Tet499 cells were sorted from immunized CD45.2 mice and transferred into CD45.1 congenic mice 
followed by immunization (Fig. 3A). The data showed a significant more increase of Tet499 than Tet212 
cells in the CD45.1 mice (Fig. 3B). In addition, the carcinogen-induced autochthonous HCC model was 
utilized to study in vivo antigen responsiveness of Tet212 and Tet499 cells to emerging AFP tumor antigen 
(Fig. 3C). We first found that the magnitude of Tet499 responses after vv boost was greater than that of 
Tet212 (Fig. 3D), suggesting Tet499 cells primed by lv underwent more extensive expansion when re-
encountering antigen expressed from vv. Tet499 cells were also able to detect emerging AFP antigen in 
autochthonous HCC and responded by expansion (the spike of Tet499 at day 140 in Fig. 3D). In contrast, 
Tet212 cells did not generate expansion by vv boost and could not generate productive response to 
emerging AFP antigen.  
 
Tet499 contain more Tscm, Tcm, and express more antiapoptotic Bcl-2 than Tet212.  
We next studied the possible mechanisms underpinning the different antigen responsiveness of Tet212 
and Tet499 cells. Memory T cells, especially Tscm and Tcm, are critical for generating antitumor effect as 
they can undergo expansion in response to tumor antigen (29-31). To study if the antigen responsiveness 
and antitumor effect of Tet212 and Tet499 cells were related to Tscm and Tcm, we stained Tet212 and Tet499 
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with CD44 and CD62L. As demonstrated in Fig. 4A, the Tet+ CD8+ cells could be grouped into 
CD44+CD62L- Teff (or effector memory, hereafter referred to as Teff), CD44+CD62L+ Tcm, and the 
CD44-CD62L+ naïve-like Tscm. We found that Tet499 contained more Tscm and Tcm than Tet212 (Fig. 4A). 
Even after in vitro stimulation, the percent of Tcm and Tscm was still higher among Tet499 (Fig. 4B). 
Further analysis showed that, different from the counterpart of naïve CD8+ T cells, the Tet499 Tscm 
expressed more of stem-like cell markers of ScaI, CD122, and CCR7 (Fig. 4C). To minimize non-specific 
binding, beads enriched CD8+ T cells were pre-blocked by Fc blocker CD16/CD32 antibody. After taking 
these measures, we verified that Tet499 contained more Tscm than Tet212 (Supplementary Fig. S3A). The 
CD44-CD62L+ Tscm also expressed higher level of CD95 than naïve CD8+ T cells, another potential 
marker of Tscm (Supplementary Fig. S3B). The presence of Tscm was then confirmed in the Tet499 cells 
by dual-color tetramer staining (Supplementary Fig. S3C).  
The resistance to antigen-induced Tet499 apoptosis may be also due to the Bcl-2 molecules (32). Indeed, 
we found that the Tscm of Tet499 expressed the highest level of Bcl-2 compared to Tcm and Teff, nearly 
to the same level as naïve CD8+ cells (Supplementary Fig. S3D). In addition, Bcl-2 level in the Tcm and 
Teff of Tet499 cells was higher than the counterparts of Tet212, suggesting that even at the Tcm and Teff 
stages, Tet499 cells can better survive antigen-induced cell death. 
Tscm undergo more in vivo expansion than Tcm and Teff upon re-encountering antigen.  
In Fig. 3B, we showed that Tet499 cells generated more re-expansion. To determine which subsets 
of Tet499 cells could undergo in vivo expansion, we sorted the Teff, Tcm, and Tscm and transferred them 
into CD45.1 mice (Fig. 5A). Because the number of Tscm and Tcm cells in the Tet499
+ population was too 
low to be efficiently collected, we sorted the Teff, Tcm, and Tscm based on the total CD8+ cells (see 
sorting strategy and purity of Tscm, Tcm, and Teff in Supplementary Fig. S4A-B). The number of 
Tet499
+Tscm, Tet499
+Tcm, and Tet499
+Teff was calculated using the percentage of Tet499
+ in the sorted 
CD8+ Tscm, Tcm, and Teff population (Supplementary Fig. S4C). Equal numbers (2000) of Tet499
+Tscm, 
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Tet499
+Tcm, and Tet499
+Teff was transferred into CD45.1 mice. Teff generated no measurable expansion. 
In contrast, the CD45.2+ CD8+ cells were detected in the CD45.1 congenic mice receiving Tscm or Tcm 
cells (Fig. 5B-C). The percent of CD45.2+Tet499 cells in the mice receiving Tscm increased by more than 
30 fold, from ~1% to ~35%, whereas the percentage of CD45.2+Tet499 cells in the mice receiving Tcm 
increased only 5 times, from ~1% to ~5% (Supplementary Fig.S4C and Fig.5B-C). This data suggests the 
Tet499
+Tscm undergo more expansion than Tet499
+Tcm in vivo after re-encountering antigen. In addition, 
after adoptive transfer of Tscm, three populations of cells, Tscm, Tcm, and Teff, were found in the mice 
(Fig.5D), suggesting that Tscm could differentiate into Tcm and Teff and maintained self-renewal 
capability.  
 
The TCR signaling strength is weaker on Tet499 than on Tet212.  
It is postulated that TCR signaling strength affects antigen-induced T-cell differentiation, 
including induction of Tscm and Tcm (29,33,34), which have a greater potential of expansion when re-
encountering the same antigen (35). To determine the TCR signaling strength of Tet212 and Tet499 cells, 
we utilized the Nur77GFP mice (25), in which the TCR signaling strength is reflected by GFP intensity on 
T cells. We found that, fresh Tet212 and Tet499 cells from immunized Nur77
GFP mice were GFP-/low prior to 
stimulation (Fig. 6A). After re-stimulation with 2µg/ml peptide in media for 4hrs, all Tet212 and ~90% of 
Tet499 cells became GFP
+, with a higher GFP level on Tet212 cells (Fig. 6A-B). The remaining GFP
-/low 
Tet499 after peptide stimulation contained more Tscm and Tcm cells; ~40% of them were Tscm and Tcm. 
Even in the GFP+ population, Tet499 contained more Tscm and Tcm than Tet212 (Supplementary Fig. S5A-
C). Peptide titration study revealed that the % and MFI of GFP+ Tet212 were higher than Tet499 at any 
concentration (Fig. 6C). For example, at 1ng/ml, 80% of Tet212 cells were GFP
+, whereas only 20% of 
Tet499 cells were GFP
+. These data suggest that TCR signaling on Tet499 is weaker than Tet212. 
15 
 
Furthermore, Tet212 GFP
+ cells had higher CD44 expression than the Tet499 GFP
+ cells (Fig. 6D), 
indicating that the Tet499 cells are in a lower activation state.  
The TCR signaling strength of Tet212 and Tet499 cells was further studied by re-stimulating the 
purified CD45.2+CD8+ T cells from immunized Nur77GFP mice with peptide-pulsed CD45.1 splenocytes. 
We found that, prior to re-stimulation, fresh Tet212 of immunized mice express higher basal level GFP 
than Tet499 cells (Fig. 6E). Tet212 could become GFP
+ even at low concentration of peptide (Fig. 6F). The 
Tet212 cells re-stimulated by splenocytes pulsed with 0.1µg/ml of AFP212 peptide expressed higher level of 
GFP than Tet499 re-stimulated by splenocytes pulsed with 10µg/ml of AFP499 peptide, suggesting that 
Tet499 TCR signaling is at least 100 times weaker than Tet212 TCR signaling.  
 
Compared to Tet212, Tet499 TCRs have higher avidity for MHC/peptide but are more downregulated 
The low reactivation threshold and stronger TCR signaling on Tet212 cells (Figs. 2 and 6) may be 
caused by high T cell avidity for cognate MHC/peptide. Thus, we conducted a tetramer binding (Fig. 7A) 
and dissociation (Fig. 7B) assays, which measure the TCR avidity for MHC/peptide complex. The data 
showed that approximately 90% of the Tet499 cells were stained with a low concentration (0.65µg/ml) of 
H-2Kb-Db/AFP499 tetramer. In contrast, to achieve 90% staining of the Tet212 cells, 10 times more 
(6.5µg/ml) of the H-2Db/AFP212 tetramer was required. In addition, the Tet499 TCR binding to 
MHC/peptide was dissociated more slowly (Fig. 7B). Thus, the Tet499 TCRs have a higher avidity for 
MHC/peptide.  
Another factor that can influence the TCR signaling strength is the amount of TCR on the  cell 
surface, which is normally downregulated after activation (36). Thus, we examined the TCR levels on 
Tet212 and Tet499 cells. The splenocytes from immunized mice were stained with antibodies to CD8, CD44, 
CD62L, TCR Vβ (Clone 57-597), plus tetramer. The TCR Vβ levels on Tet+ CD8+ T cells were compared 
to Tet–CD44–CD62L+ naïve CD8+ T cells. Our data demonstrated that TCRs on Tet499 were more 
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downregulated (Fig.7C-E). Tet499 had only 40% of the TCRs as naïve CD8
+ cells.  In contrast, Tet212 had 
~80% of the TCRs as naïve CD8+ cells. By direct comparison, the Tet499 had approximately half the TCRs 
of Tet212 cells (Fig. 7F). The kinetic analysis of TCR downregulation showed that TCR downregulation 
on Tet212 was mild and transient (Fig. 7G). In contrast, TCR downregulation on Tet499 was severe and 
persistent. As the antibody to TCR Vβ staining may be interfered with by tetramers that compete for the 
same TCR, the CD3 level on Tet212 and Tet499 cells was thus measured to determine TCR downregulation. 
The data showed that CD3 was also more downregulated on Tet499 than on Tet212 (Supplementary Fig. 
S6A-D). Together, our data showed that, the Tet499 TCRs have higher avidity for MHC/peptide, but its 
level is more downregulated after activation, which may result in ensuing weaker TCR signaling and 
higher threshold of re-activation.  
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Discussion 
Our findings associate the antitumor effect of vaccine-activated CD8+ T-cells with their antigen 
sensitivity and activation/differentiation states. First, the antigen sensitivity of two AFP-specific CD8+ T-
cells, Tet212 and Tet499, is different. Tet212 have a lower threshold of re-activation and are sensitive to 
antigen stimulation, but become exhausted and apoptotic when antigen persists, and generate no 
antitumor effect in vivo. In contrast, Tet499 have a higher threshold of re-activation and are more resistant 
to antigen stimulation, but can survive persistent tumor antigen, maintain their effector function, and 
generate a potent antitumor effect in vivo. Secondly, the vaccine-activated Tet212 and Tet499 cells are at 
different differentiation and activation state. Tet499 cells are at a lower activation state and consist of 
diverse subsets at different differentiation stages, including Tscm and Tcm. In contrast, there are no Tscm 
and few Tcm in Tet212. The Tet499 Tscm can undergo extensive in vivo expansion when re-encountering 
antigen. Thirdly, the TCR signaling on Tet212 is stronger and associated with mild and transient TCR 
downregulation. In contrast, the Tet499 TCR signaling is weaker, likely due to severe and persistent TCR 
downregulation.  
TCR signaling strength correlates to the activation and magnitude of antigen-specific T cells (37-39). 
Indeed, data from Nur77GFP mice showed that the TCR signaling on Tet212 was stronger, corresponding to 
a higher magnitude of Tet212 response by immunization (24). But, on the other hand, strong TCR 
signaling can negatively affect the induction of Tscm (29,40). In agreement with this argument, the Tet499, 
but not Tet212 contains Tscm. Stem-like memory immune cells were proposed by Fearon et al (41). The 
Tscm was found to cause graft vs host disease (35). Gattinoni et al showed that the TCR transgenic 
gp100-specific Tscm generated in vitro by inhibiting Wnt signaling had a better antitumor effect (42). 
They further found that human Tscm mediated strong antitumor effect in mice bearing human tumors (43). 
In a retrospective study, Speiser and colleagues found that yellow fever vaccine-induced Tscm in human 
correlated to long-term protection (44). Here we show that cancer vaccine can elicit Tscm in vivo, which 
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is associated with TCR downregulation and weak TCR signaling, and correlates with stronger antitumor 
effect.  
The engagement of TCR and MHC/peptide and proper TCR signaling are also needed for the re-
activation of vaccine-induced T cells to recognize and kill tumor cells. T cells with higher basal level of 
TCR signaling are more ready for activation (45,46).  Even though the Tet212 and Tet499 activated by 
vaccine are not naïve cells, their re-activation seems also correlate to their basal TCR signaling. Tet212 
have a higher TCR signaling strength and are more ready for re-activation and consequently also suffers 
from activation induced cell death when antigen persists. In contrast, the Tet499 cells with weaker TCR 
signaling survive persistent antigen stimulation and generate a stronger antitumor effect. This is consistent 
with previous hypothesis that TCR downregulation may protect T cells from excessive signaling (47). 
Thus, TCR downregulation and weaker TCR signaling on the activated T cells in the effector phase may 
protect them from antigen-induced exhaustion and apoptosis, especially in the tumor lesions where the 
antigen is abundant and the stimulation is likely persistent. But the high concentration of antigens in 
tumor lesion and the prolonged engagement of T cells and tumor cells will compensate for the lower TCR 
level and generate sufficient accumulative signaling strength to activate Tet499 cells to kill tumor cells.  
The association of weak TCR signaling with stronger antitumor effect of T cells seems counter-
intuitive. Our finding of Tet499 TCR downregulation associated with a strong antitumor effect is also in 
contrast to a report showing that TCR downregulation limits their efficacy of controlling microbial 
infection (48). We reason that this is likely due to the difference of antigen level and antigen stimulation 
duration between microbial infections and tumor lesion. In acute infections, the microbial antigen is 
transient, and thus T cells with higher level or sensitive TCR should not be exhausted and are more 
effective to eliminate the infection because of the stronger engagement of TCR and MHC/peptide. On the 
other hand, in tumor lesion, the T cells are immersed in a pool of tumor antigens for a prolonged period of 
time, thus T cells with sensitive threshold of re-activation will likely be driven to exhaustion. Only the T 
cells with weaker TCR signaling may survive persistent antigen stimulation and generate antitumor 
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effects. In agreement with this theory, in chronic persistent viral infection, T cells are exhausted (49). The 
report that T cells activated with intermediate affinity peptides (thus intermediate strength of TCR 
signaling) generate a better antitumor effect (50) is also in agreement with our data.  
Based on these findings, we propose a model (Supplementary Fig.S7), in which the TCR signaling 
strength and the threshold of activation controls the state of T-cell activation, the generation of Tscm, 
antigen responsiveness, and the antitumor effect of the vaccine-activated CD8+ T cells. In this model, 
initial high affinity TCR-MHC/peptide complex engagement results in T-cell activation and concurrently 
generates feedback to downregulate TCR on activated T cells, weakening the TCR signaling to avoid 
over-activation of T cells in the priming phase. The weakened TCR signaling will allow some activated T 
cells to halt differentiation at Tscm stage to reserve their potential to generate better responsiveness and 
stronger antitumor effect when they re-encounter cognate antigen in tumor lesions. Thirdly, the weakened 
TCR signaling on Teff will protect them from exhaustion and apoptosis upon re-encountering persistent 
antigen in tumor lesion. In contrast, if the TCR downregulation is mild and transient, TCR signaling will 
likely drive all activated T cells to become terminal Teff, which not only decrease Tscm, but also 
predispose the Teff to exhaustion and apoptosis when they re-encounter antigen in tumor lesion.  
In this model, we attribute the different TCR signaling strength and antigen sensitivity of Tet212 and 
Tet499 cells to their different TCR downregulation. However, these differences may also be due to the 
inherent difference of internal signaling pathways inside the Tet212 and Tet499 cells. Whether the high 
affinity TCR-MHC/peptide engagement also reduces the internal signaling pathway is not clear, nor is the 
inherent signaling difference between naive Tet212 and Tet499 cells.  Even though our data support that the 
different antigen responsiveness of vaccine-activated Tet212 and Tet499 cells relates to their different TCR 
downregulation and signaling strength, further studies should be done to investigate whether the naïve 
Tet212 and Tet499 cells are different in their antigen responsiveness. If naïve Tet499 and Tet212 cells indeed 
have inherent signaling difference that is beyond the TCR level, the T cells with higher threshold of 
activation and capability of resisting antigen-induced cell death may be the ideal host cells for generating 
20 
 
TCR and chimeric antigen receptor (CAR) gene engineered T cells for immunotherapy of solid tumors, 
where the TCR or CAR gene engineered T cells need to survive persistent antigen stimulation and 
generate antitumor effect.  
This current study also raises questions in cancer vaccines and immunotherapy. The first question is 
whether TCR signaling strength on any antigen-specific T cells can be manipulated to enhance Tscm 
generation and to prevent exhaustion in tumor lesion. Secondly, how should cancer vaccine and 
immunization strategies be devised to find the right balance between eliciting sufficient number of tumor-
specific T cells while inducing Tscm to achieve the maximal antitumor effect? Investigation into these 
questions should help develop more effective cancer vaccines and enhance the antitumor efficacy of 
current immunotherapies.  
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Figure Legends 
Fig. 1 The lv-immunized mouse splenocytes demonstrate CTL activity after AFP499, but not AFP212, 
peptide re-stimulation; and the Tet499, but not Tet212, cells yield antitumor effects in vivo. (A) The 
splenocytes were re-stimulated with 2µg/ml of AFP212 or AFP499 peptide in the media for 6 days before 
CTL assay. (B) The CTL activity of mouse splenocytes after re-stimulation with AFP212 or AFP499 was 
summarized from 3 mice in each group. The experiment was repeated 4 times with similar results. (C) 
Lvs expressing full-length opt-AFP, AFP142, and AFP164 fragments were illustrated. (D) Mice (5 in 
each group) immunized with indicated lv were challenged with EL4-AFP tumor cells. Tumor growth was 
monitored. The experiment was repeated 3 times with similar results.  
Fig. 2 Tet212 have a lower re-activation threshold, and undergo more exhaustion and apoptosis than 
Tet499 in response to antigen re-stimulation. The beads-purified CD45.2
+CD8+ T-cells were stimulated 
with peptide-pulsed naïve CD45.1 splenocytes or with peptide in media for 4days. (A) Representative 
plots of tetramer staining were presented. A summary of peptide-dose effect on Tet212 and Tet499 cell was 
also presented. * indicates peptides directly added to media. “0” means no re-stimulation. (B and C) The 
Tet212 and Tet499 cells after stimulation were analyzed for the expression of PD1 (B) and Annexin-V (C). 
Representative histograms and the dose-dependent induction of PD1 (B) and Annexin-V (C) (% and MFI) 
on Tet212 and Tet499 cells were presented. FMO: FMO: fluorescence minus one (anti-PD1 antibody) 
control. (D) The IFN production of CD45.2+CD8+ T-cells was analyzed. Representative IFN 
intracellular staining was shown. The dose response of peptide on IFN (% and MFI) production by Tet212 
and Tet499 cells was also summarized. The % of IFN-producing Tet
+ were calculated by dividing the % 
of IFN+ CD45.2+CD8+ T-cells by the % of Tet+ cells of the same mice (Fig. 2A). (E) The inverse 
correlation of PD1 and IFN (MFI) of Tet212, and the direct correlation of PD1 and IFN of Tet499
+ cells 
were derived from 2B and 2D. Mean ± SE was shown. Three mice were in each group and the experiment 
was repeated twice with similar data.  
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Fig. 3 Tet499 undergo more expansion in vivo than Tet212 and respond to emerging tumor antigen. (A) 
Tet212 and Tet499 cells (5 x 10
5) were sorted from immunized CD45.2 mice and transferred into CD45.1 
mice followed by vaccination. (B) Summarized was the kinetics of the CD45.2+CD8+Tet212
+ and 
CD45.2+CD8+Tet499
+ cells in CD45.1 mice. Three mice were in each group. The experiment was repeated 
twice with similar results. (C) Shown is the experimental design for studying Tet212 and Tet499 responses 
to vv-boost and to emerging tumor antigen AFP in autochthonous HCC model. (D) The kinetics of Tet212 
and Tet499 responses in the DEN-induced mice was presented. Five mice were in each group, and the 
experiment was repeated twice with similar results.  
Fig. 4 More Tscm is found in Tet499 than in Tet212. (A and B) Splenocytes from the immunized mice 
were either directly stained (A) or were re-stimulated in vitro for 3 days with AFP212 or AFP499 peptide 
and then stained (B) for CD8, tetramer, CD44, and CD62L. Representative dot plots of Tscm, Tcm, and 
Teff in the Tet212 and Tet499 cells were shown. A summary data of Tcm and Tscm of 12 mice from 3 
experiments are presented. (C) The Tscm of Tet499 cells and naive CD44
-CD62L+ CD8+ cells were stained 
for the stem-like markers ScaI, CD122, and CCR7. Representative histograms and a summary data of 4 
mice were shown. FMO: fluorescence minus one control (minus ScaI, CD122, or CCR7). The experiment 
was done twice with similar results. 
Fig. 5 Tscm can undergo robust expansion and differentiate into Tcm and Teff in vivo. (A) The 
experimental scheme is illustrated (See Supplementary Fig.S5 for sorting strategy). Equal number (2000 
cells) of the Tscm, Tcm, and Teff of Tet499+ cells were transferred into CD45.1 congenic mice followed 
by immunization.  (B) Presented were the representative dot plots of CD45.2+CD8+ and Tet499 cells in 
CD45.1 mouse blood after adoptive cell transfer. (C) The kinetics of CD45.2+CD8+Tet499
+ cells after 
Tscm and Tcm transfer into CD45.1 mice was shown. A summary of the fold of increase of Tet499 after 
Tscm and Tscm transfer was also shown. Three mice were in each group. The experiment was repeated 
twice with similar results. (D) Shown is the differentiation of the CD45.2+ Tscm and Tcm in CD45.1 mice. 
The representative plots of 3 mice were shown.  
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Fig. 6 The TCR signaling strength is weaker on Tet499 than on Tet212. (A-D) The splenocytes of 
immunized Nur77GFP mice were re-stimulated 4hrs with 1µg/ml of AFP212 or AFP499 peptide in media, 
and GFP on the Tet212 and Tet449 cells were analyzed. (A) The representative histograms showed the GFP 
level on Tet212 and Tet499
 cells before (open) and after (filled) re-stimulation. (B) The % and MFI of GFP+ 
and GFP-/lo Tet212 and Tet499 cells was summarized from 3 mice. (C) A summary of dose-dependent 
induction of GFP+ cells (% and MFI) was presented. (D) Histogram showed the representative CD44 
staining. A summary of CD44 level on the Tet212 and Tet499 cells of 3 mice was also presented. The 
experiment was repeated twice with similar observations. (E and F) The beads-purified CD8 T-cells from 
immunized Nur77 mice were analyzed for GFP expression before and after stimulation with peptide-
pulsed naïve CD45.1 splenocytes. (E) The representative histogram showed the basal level of GFP 
expression on Tet212 (filled) and Tet499 (open) prior to re-stimulation. A summary of basal GFP level from 
4 mice was also presented. (F) Shown were the GFP level on CD45.2+CD8+Tet212 (filled) and on 
CD45.2+CD8+Tet499 (open) cells after 24hr stimulation with naïve CD45.1 splenocytes pulsed with 
indicated AFP212 or AFP499 peptides. A summary showing the dose-dependent induction of GFP (% and 
MFI) of 4 mice was also presented (Mean ± SE). The experiment was repeated twice with similar results.     
Fig. 7 Tet499 TCRs have higher avidity for MHC/peptide than Tet212, but their level is significantly 
more downregulated. (A and B) Shown was the data of tetramer binding and dissociation assays. Data 
shown are representative from one of 3 mice. The experiment was repeated twice with similar results. (C 
and D) The TCR level of Tet212 (C) and Tet499 (D) was measured. Splenocytes from the lv-vv immunized 
mice were stained with indicated antibodies. The CD8+ and TCR Vβ+ cells were analyzed for tetramer 
staining and CD44 and CD62L. Among the Tet- population, CD44-CD62L+ cells were considered naïve 
cells, while the Tet+ cells were considered activated T cells. The TCR Vβ level on the Tet+ CD8+ cells 
(red line) and Tet- CD44-CD62L+ naïve CD8+ cells (black line) were compared. (E and F) The percent of 
Tet212 and Tet499 TCR downregulation (E) and the absolute MFI of Tet212 and Tet499 TCR (F) were 
compared. Three mice were in each group. Mean ± SE was shown. (G) The kinetics of TCR 
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downregulation on Tet212 and Tet499 was presented. At each time point, blood T cells were analyzed for 
TCR downregulation as stated above. Three mice were in each group. Mean ± SE was shown at each time 
point. The experiment was repeated twice with similar results. 
 
 







